TG Therapeutics, Inc. Dividend History (TGTX)

About TG Therapeutics, Inc.

TG Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for B-cell diseases, such as multiple sclerosis and hematologic cancers. Founded in 2012, the company is headquartered in New York City. Michael S. Weiss serves as the Executive Chairman and CEO, guiding the company's strategic direction and operations. TG Therapeutics has gained attention for its oral B-cell therapy, ublituximab, which has shown promise in treating certain forms of cancer and autoimmune diseases. While the company's primary focus is on clinical advancements, financial performance can vary as it continues to invest in research and development. Its dedication to improving patient outcomes positions TG Therapeutics as a noteworthy player in the biotech industry.